Cargando…
Optimal Thyrotropin Suppression Therapy in Low-Risk Thyroid Cancer Patients after Lobectomy
Background: This study aimed to identify the clinical results after thyrotropin suppression therapy (TST) cessation and evaluated clinical factors associated with successful TST cessation. Methods: Patients who underwent lobectomy due to low-risk papillary thyroid carcinoma (PTC) were included in th...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6780946/ https://www.ncbi.nlm.nih.gov/pubmed/31443521 http://dx.doi.org/10.3390/jcm8091279 |
_version_ | 1783457261679542272 |
---|---|
author | Lee, Yu-Mi Jeon, Min Ji Kim, Won Woong Sung, Tae-Yon Chung, Ki-Wook Shong, Young Kee Hong, Suck Joon |
author_facet | Lee, Yu-Mi Jeon, Min Ji Kim, Won Woong Sung, Tae-Yon Chung, Ki-Wook Shong, Young Kee Hong, Suck Joon |
author_sort | Lee, Yu-Mi |
collection | PubMed |
description | Background: This study aimed to identify the clinical results after thyrotropin suppression therapy (TST) cessation and evaluated clinical factors associated with successful TST cessation. Methods: Patients who underwent lobectomy due to low-risk papillary thyroid carcinoma (PTC) were included in this study. We compared clinical characteristics and outcomes between patients who succeeded to stop TST and failed to stop TST. Results: A total of 363 patients were included in the study. One hundred and ninety-three patients (53.2%, 193/363) succeeded to stop TST. The independent associated factors for successful TST cessation were the preoperative thyroid-stimulating hormone (TSH) level and the maintenance period of TST. Patients with low TSH level showed a higher success rate for levothyroxine (LT4) cessation than patients with high TSH level (1.79 ± 1.08 and 2.76 ± 1.82 mU/L, p < 0.001). Patients who failed to discontinue TST showed a longer maintenance period of TST than patients who succeeded to discontinue TST (54.09 ± 17.44 and 37.58 ± 17.68 months, p < 0.001). Conclusions: Preoperative TSH level and maintenance period of TST are important factors for successful cessation of TST. If TST cessation is planned for patients who are taking LT4 after lobectomy, a higher success rate of TST cessation is expected with low preoperative TSH level and early cessation of LT4. |
format | Online Article Text |
id | pubmed-6780946 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-67809462019-10-30 Optimal Thyrotropin Suppression Therapy in Low-Risk Thyroid Cancer Patients after Lobectomy Lee, Yu-Mi Jeon, Min Ji Kim, Won Woong Sung, Tae-Yon Chung, Ki-Wook Shong, Young Kee Hong, Suck Joon J Clin Med Article Background: This study aimed to identify the clinical results after thyrotropin suppression therapy (TST) cessation and evaluated clinical factors associated with successful TST cessation. Methods: Patients who underwent lobectomy due to low-risk papillary thyroid carcinoma (PTC) were included in this study. We compared clinical characteristics and outcomes between patients who succeeded to stop TST and failed to stop TST. Results: A total of 363 patients were included in the study. One hundred and ninety-three patients (53.2%, 193/363) succeeded to stop TST. The independent associated factors for successful TST cessation were the preoperative thyroid-stimulating hormone (TSH) level and the maintenance period of TST. Patients with low TSH level showed a higher success rate for levothyroxine (LT4) cessation than patients with high TSH level (1.79 ± 1.08 and 2.76 ± 1.82 mU/L, p < 0.001). Patients who failed to discontinue TST showed a longer maintenance period of TST than patients who succeeded to discontinue TST (54.09 ± 17.44 and 37.58 ± 17.68 months, p < 0.001). Conclusions: Preoperative TSH level and maintenance period of TST are important factors for successful cessation of TST. If TST cessation is planned for patients who are taking LT4 after lobectomy, a higher success rate of TST cessation is expected with low preoperative TSH level and early cessation of LT4. MDPI 2019-08-22 /pmc/articles/PMC6780946/ /pubmed/31443521 http://dx.doi.org/10.3390/jcm8091279 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lee, Yu-Mi Jeon, Min Ji Kim, Won Woong Sung, Tae-Yon Chung, Ki-Wook Shong, Young Kee Hong, Suck Joon Optimal Thyrotropin Suppression Therapy in Low-Risk Thyroid Cancer Patients after Lobectomy |
title | Optimal Thyrotropin Suppression Therapy in Low-Risk Thyroid Cancer Patients after Lobectomy |
title_full | Optimal Thyrotropin Suppression Therapy in Low-Risk Thyroid Cancer Patients after Lobectomy |
title_fullStr | Optimal Thyrotropin Suppression Therapy in Low-Risk Thyroid Cancer Patients after Lobectomy |
title_full_unstemmed | Optimal Thyrotropin Suppression Therapy in Low-Risk Thyroid Cancer Patients after Lobectomy |
title_short | Optimal Thyrotropin Suppression Therapy in Low-Risk Thyroid Cancer Patients after Lobectomy |
title_sort | optimal thyrotropin suppression therapy in low-risk thyroid cancer patients after lobectomy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6780946/ https://www.ncbi.nlm.nih.gov/pubmed/31443521 http://dx.doi.org/10.3390/jcm8091279 |
work_keys_str_mv | AT leeyumi optimalthyrotropinsuppressiontherapyinlowriskthyroidcancerpatientsafterlobectomy AT jeonminji optimalthyrotropinsuppressiontherapyinlowriskthyroidcancerpatientsafterlobectomy AT kimwonwoong optimalthyrotropinsuppressiontherapyinlowriskthyroidcancerpatientsafterlobectomy AT sungtaeyon optimalthyrotropinsuppressiontherapyinlowriskthyroidcancerpatientsafterlobectomy AT chungkiwook optimalthyrotropinsuppressiontherapyinlowriskthyroidcancerpatientsafterlobectomy AT shongyoungkee optimalthyrotropinsuppressiontherapyinlowriskthyroidcancerpatientsafterlobectomy AT hongsuckjoon optimalthyrotropinsuppressiontherapyinlowriskthyroidcancerpatientsafterlobectomy |